Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 304

1.

Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.

Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell MJ.

PLoS Pathog. 2013;9(5):e1003389. doi: 10.1371/journal.ppat.1003389. Epub 2013 May 30.

2.

Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.

Willet M, Kurup D, Papaneri A, Wirblich C, Hooper JW, Kwilas SA, Keshwara R, Hudacek A, Beilfuss S, Rudolph G, Pommerening E, Vos A, Neubert A, Jahrling P, Blaney JE, Johnson RF, Schnell MJ.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S414-24. doi: 10.1093/infdis/jiv251. Epub 2015 Jun 10.

3.

Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.

Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, Paragas J, Schnell MJ.

J Virol. 2011 Oct;85(20):10605-16. doi: 10.1128/JVI.00558-11. Epub 2011 Aug 17.

4.

Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.

Papaneri AB, Wirblich C, Cooper K, Jahrling PB, Schnell MJ, Blaney JE.

Vaccine. 2012 Sep 21;30(43):6136-41. doi: 10.1016/j.vaccine.2012.07.073. Epub 2012 Aug 8.

5.

Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.

Konduru K, Shurtleff AC, Bradfute SB, Nakamura S, Bavari S, Kaplan G.

PLoS One. 2016 Sep 13;11(9):e0162446. doi: 10.1371/journal.pone.0162446. eCollection 2016.

6.

Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine.

Papaneri AB, Bernbaum JG, Blaney JE, Jahrling PB, Schnell MJ, Johnson RF.

Virus Res. 2015 Feb 2;197:54-8. doi: 10.1016/j.virusres.2014.11.028. Epub 2014 Dec 4.

7.

An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.

Johnson RF, Kurup D, Hagen KR, Fisher C, Keshwara R, Papaneri A, Perry DL, Cooper K, Jahrling PB, Wang JT, Ter Meulen J, Wirblich C, Schnell MJ.

J Infect Dis. 2016 Oct 15;214(suppl 3):S342-S354. Epub 2016 Jul 24.

8.

Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.

Vu H, Shulenin S, Grolla A, Audet J, He S, Kobinger G, Unfer RC, Warfield KL, Aman MJ, Holtsberg FW.

Antiviral Res. 2016 Feb;126:55-61. doi: 10.1016/j.antiviral.2015.11.012. Epub 2015 Dec 8.

9.

Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.

Schweneker M, Laimbacher AS, Zimmer G, Wagner S, Schraner EM, Wolferst├Ątter M, Klingenberg M, Dirmeier U, Steigerwald R, Lauterbach H, Hochrein H, Chaplin P, Suter M, Hausmann J.

J Virol. 2017 May 12;91(11). pii: e00343-17. doi: 10.1128/JVI.00343-17. Print 2017 Jun 1.

10.

Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.

Lingemann M, Liu X, Surman S, Liang B, Herbert R, Hackenberg AD, Buchholz UJ, Collins PL, Munir S.

J Virol. 2017 Apr 28;91(10). pii: e02469-16. doi: 10.1128/JVI.02469-16. Print 2017 May 15.

11.

Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.

DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A.

Vaccine. 2010 Dec 10;29(1):17-25. doi: 10.1016/j.vaccine.2010.10.024. Epub 2010 Oct 27.

12.

Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.

Aviles J, Bello A, Wong G, Fausther-Bovendo H, Qiu X, Kobinger G.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S389-97. doi: 10.1093/infdis/jiv175. Epub 2015 Jun 2.

PMID:
26038398
13.

Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.

Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, Pratt WD, Hart MK, Dong JY.

J Virol. 2006 Mar;80(6):2738-46.

14.

Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates.

Marzi A, Halfmann P, Hill-Batorski L, Feldmann F, Shupert WL, Neumann G, Feldmann H, Kawaoka Y.

Science. 2015 Apr 24;348(6233):439-42. doi: 10.1126/science.aaa4919. Epub 2015 Mar 26.

15.

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.

Meyer M, Garron T, Lubaki NM, Mire CE, Fenton KA, Klages C, Olinger GG, Geisbert TW, Collins PL, Bukreyev A.

J Clin Invest. 2015 Aug 3;125(8):3241-55. doi: 10.1172/JCI81532. Epub 2015 Jul 13.

16.

Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species.

Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, Stanley D, Fabozzi G, Nichol ST, Ksiazek TG, Rollin PE, Wahl-Jensen V, Bailey M, Jahrling PB, Roederer M, Koup RA, Sullivan NJ.

PLoS Pathog. 2010 May 20;6(5):e1000904. doi: 10.1371/journal.ppat.1000904.

17.

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.

Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, Geisbert JB, Mire CE, Hamm S, Nowak B, Egan MA, Geisbert TW, Eldridge JH, Feldmann H, Clarke DK.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S443-51. doi: 10.1093/infdis/jiv316. Epub 2015 Jun 24.

18.

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.

Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, Feldmann H, Messaoudi I.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8. doi: 10.1073/pnas.1209591110. Epub 2013 Jan 14.

19.

An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.

Wu S, Kroeker A, Wong G, He S, Hou L, Audet J, Wei H, Zhang Z, Fernando L, Soule G, Tran K, Bi S, Zhu T, Yu X, Chen W, Qiu X.

J Infect Dis. 2016 Oct 15;214(suppl 3):S326-S332. Epub 2016 Aug 4. Erratum in: J Infect Dis. 2017 Jan 1;215(1):165.

20.

Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.

Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, Xu RH, Zhou B, Lu H, Kwilas SA, Hahn TJ, Kpamegan E, Hooper J, Carrion R Jr, Glenn G, Smith G.

Vaccine. 2016 Apr 7;34(16):1927-35. doi: 10.1016/j.vaccine.2016.02.033. Epub 2016 Feb 24.

Supplemental Content

Support Center